@article{oai:niigata-u.repo.nii.ac.jp:00002152,
 author = {Sato, Naoko and Kishi, Kenji and Toba, Ken and Watanabe, Kenichi and Itoh, Hiromi and Narita, Miwako and Takahashi, Masuhiro and Aizawa, Yoshifusa},
 issue = {7},
 journal = {Leukemia Research, Leukemia Research},
 month = {Jul},
 note = {Like CD19 or CD56, CD22 in non-lymphoid leukemia has been considered an aberrantly expressed antigen. CD22 had been believed to be restricted to B lymphoid, however, it was also found to be expressed in human basophils. Mature basophils are unique granulocytes expressing CD13, CD22 and CD25. To estimate whether the expression of CD22 in non-lymphoid leukemia is aberrant or related to basophilic character, we analyzed 108 patients with primary and secondary leukemia. Among non-lymphoid leukemias, surface CD22 expression was more frequently observed in peroxidase-negative AML and secondary leukemia, and was usually observed simultaneously with CD13 and CD25. Samples obtained from 17 cases were further analyzed, and all the FcεR1-positive cases were observed in peroxidase-negative AML and secondary non-lymphoid leukemia, and mostly expressed CD13, CD22 and CD25. Therefore, surface CD22 expression in non-lymphoid leukemia was thought to relate to basophilic phenotype in some cases. Like CD22, some of the so-called aberrantly expressed antigens may not actually be aberrant, but are expressed in a stage of differentiation and maturation of progenitors. Moreover, CD22 may be one of target molecules for treatment of CD22-positive, poorly prognostic leukemia.},
 pages = {691--698},
 title = {Simultaneous expression of CD13, CD22 and CD25 is related to the expression of FcεR1 in non-lymphoid leukemia},
 volume = {28},
 year = {2004}
}